CA2171289C - Il8 inhibitors - Google Patents

Il8 inhibitors Download PDF

Info

Publication number
CA2171289C
CA2171289C CA002171289A CA2171289A CA2171289C CA 2171289 C CA2171289 C CA 2171289C CA 002171289 A CA002171289 A CA 002171289A CA 2171289 A CA2171289 A CA 2171289A CA 2171289 C CA2171289 C CA 2171289C
Authority
CA
Canada
Prior art keywords
receptor
amino acid
acid sequence
binding
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002171289A
Other languages
English (en)
French (fr)
Other versions
CA2171289A1 (en
Inventor
Patricia Tekamp-Olson
Guy Mullenbach
Mary Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CA2171289A1 publication Critical patent/CA2171289A1/en
Application granted granted Critical
Publication of CA2171289C publication Critical patent/CA2171289C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002171289A 1993-09-14 1994-09-13 Il8 inhibitors Expired - Fee Related CA2171289C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/121,105 US6448379B1 (en) 1993-09-14 1993-09-14 IL8 inhibitors
US08/121,105 1993-09-14
PCT/US1994/010356 WO1995007934A2 (en) 1993-09-14 1994-09-13 Il8 inhibitors

Publications (2)

Publication Number Publication Date
CA2171289A1 CA2171289A1 (en) 1995-03-23
CA2171289C true CA2171289C (en) 2007-04-10

Family

ID=22394586

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002171289A Expired - Fee Related CA2171289C (en) 1993-09-14 1994-09-13 Il8 inhibitors

Country Status (11)

Country Link
US (2) US6448379B1 (cg-RX-API-DMAC7.html)
EP (3) EP1283217B1 (cg-RX-API-DMAC7.html)
JP (3) JPH09502725A (cg-RX-API-DMAC7.html)
AT (2) ATE388168T1 (cg-RX-API-DMAC7.html)
AU (1) AU697190B2 (cg-RX-API-DMAC7.html)
CA (1) CA2171289C (cg-RX-API-DMAC7.html)
DE (2) DE69435083T2 (cg-RX-API-DMAC7.html)
DK (1) DK1283217T3 (cg-RX-API-DMAC7.html)
ES (1) ES2302774T3 (cg-RX-API-DMAC7.html)
PT (1) PT1283217E (cg-RX-API-DMAC7.html)
WO (1) WO1995007934A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6283896A (en) * 1995-06-20 1997-01-22 Chiron Corporation Interleukin-8 receptor binding compounds
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0939634A4 (en) * 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
ES2156534B1 (es) * 1999-02-03 2002-02-01 Smithkline Beecham Sa Nuevos inhibidores de la interaccion entre la interleuquina-8 y sus receptores
US20030186889A1 (en) * 2000-03-31 2003-10-02 Wolf-Georg Forssmann Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
NZ541050A (en) * 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5856457A (en) * 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor

Also Published As

Publication number Publication date
WO1995007934A2 (en) 1995-03-23
CA2171289A1 (en) 1995-03-23
EP1932856A2 (en) 2008-06-18
PT1283217E (pt) 2008-06-11
EP1283217B1 (en) 2008-03-05
DE69431843T2 (de) 2003-07-10
JP4122321B2 (ja) 2008-07-23
AU697190B2 (en) 1998-10-01
EP0719285A1 (en) 1996-07-03
EP0719285B1 (en) 2002-12-04
JPH09502725A (ja) 1997-03-18
DE69435083D1 (de) 2008-04-17
ATE229036T1 (de) 2002-12-15
US6436390B1 (en) 2002-08-20
JP2005023085A (ja) 2005-01-27
WO1995007934A3 (en) 1995-04-13
JP2008169227A (ja) 2008-07-24
DE69431843D1 (de) 2003-01-23
EP1932856A3 (en) 2009-09-30
ES2302774T3 (es) 2008-08-01
EP1283217A3 (en) 2003-09-17
EP1283217A2 (en) 2003-02-12
US6448379B1 (en) 2002-09-10
DK1283217T3 (da) 2008-07-07
AU7834894A (en) 1995-04-03
ATE388168T1 (de) 2008-03-15
DE69435083T2 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
JP2008169227A (ja) Ｉｌ８阻害剤
US7101689B2 (en) Interleukin-18 binding proteins, their preparation and use
KR100496063B1 (ko) 신규단백질 및 그 제조방법
US7858326B2 (en) Method of diagnosis of inflammatory disease using eotaxin antibodies
CA2358693A1 (en) Anti-ccr4 antibodies and methods of use therefor
WO2001064754A1 (en) Gene recombinant antibody and its fragment
EP1167389B1 (en) Antibodies against the protein SEMP1, methods for their production and uses thereof
JP3455743B2 (ja) ヒトｐｄｇｆベータ・レセプタに対する阻害性免疫グロブリン・ポリペプチド
UA129672C2 (uk) Антитіло до trem-1 та його застосування
JPH08503463A (ja) Ｃ−ｃｃｋｒ−１，ｃ−ｃケモカインレセプター
JPH10507646A (ja) マクロファージ由来ケモカインおよびケモカインアナログ
RU2126836C1 (ru) Моноклональное антитело к гликопротеину р человека
CN100391973C (zh) 分离树突状细胞膜蛋白基因
KR20080105111A (ko) 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
WO1999026977A1 (en) Novel receptors opg-2
JP4482235B2 (ja) 哺乳動物ランゲルハンス細胞抗原に対する抗体およびそれらの使用
US20060088501A1 (en) Duffy antigen receptor for chemokines and use thereof
EP1167387A1 (en) Antibodies against SEMP1, methods for their production and uses thereof
JP3472854B2 (ja) 新規タンパク質およびその用途
JP2022537544A (ja) Ｊｃウイルスに対するモノクローナル抗体
JPH11302193A (ja) 血管新生阻害剤
JP2001103980A (ja) 新規タンパク質およびその用途
KR20020007329A (ko) 신규 단백질 및 그의 용도

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed